CardiologyTalk

Our goal is to bridge the educational gap confronting medical cardiologist and researchers with video interviews of principal investigators.

[CardiologyTalk @CardiologyTalk]

Michael H. Davidson, MD, @mdavidsonmd @NewAmsPharma shares groundbreaking results from the ROSE2 Trial on Obacetrapib!

Discover a remarkable LDL cholesterol reduction with Obacetrapib + Ezetimibe, paving the way for aggressive LDL-C goals. 🎯👏

[video] https://t.co/DpMtKPB7V5

[CardiologyTalk @CardiologyTalk]

🔬 Marc S. Sabatine, MD, from @BrighamWomens, pioneers MK0616, a Merck PCSK9 inhibitor. LDL cholesterol drops by 60.9% in hypercholesterolemia patients—a potential healthcare game-changer!

[video]https://t.co/LdKqGirk3L

#CardioResearch #LDLCholesterol #Innovation 🌟

[CardiologyTalk @CardiologyTalk]

📢 Obacetrapib & Edizumab combo ROSE2 positive trial results in reduction of LDL cholesterol.

Watch Michael Davidson @mdavidsonmd @NewAmsPharma discuss the results https://t.co/DpMtKPB7V5

[CardiologyTalk @CardiologyTalk]

Dr. Mason The study highlights the impact of mineral oil, corn oil, EPA, and DHA on phospholipid membrane oxidation rates. @BrighamWomens #Amarincorp #DeepakBhattMD #SamuelSherrattMD #PeterLibbyMD #ACC23 #WCCardio

[CardiologyTalk @CardiologyTalk]

Icosapent Ethyl from 🥼 Professor Philippe Steg's discussion on the REDUCE-IT trial. Exciting to explore the remarkable benefits for patients with recent ACS. @APHP #PhilippeStegMD #ACC23 #WCCardio

Watch and Share the Video Here:
https://t.co/I51tabWiz8

[CardiologyTalk @CardiologyTalk]

@PrestonMasonPhD 🩺- How EPA can modulate platelet activation and thrombosis proteins in vascular endothelial cells during inflammation. @BrighamWomens #DeepakBhattMD #SamuelSherrattMD #PeterLibbyMD #ACC23 #WCCardio

Watch and Share the Video Here:
https://t.co/2muPhySdHU

[CardiologyTalk @CardiologyTalk]

Atrial Fibrillation SOC: An Electrophysiologist Review [2022] @DJ_Lakkireddy @bariatricsurgkc #Electrophysiology #CardioTwitter

https://t.co/3DXYsaXiOK

[CardiologyTalk @CardiologyTalk]

EV ICD Pivotal Study: Will This Eliminate Complications? @drpaulfriedman @MayoClinic @MayoClinicCV #CardioTwitter

https://t.co/MfJFexfPNb

[CardiologyTalk @CardiologyTalk]

EV ICD Pivotal Study: Will This Eliminate Complications? @drpaulfriedman @MayoClinic @MayoClinicCV #CardioTwitter

https://t.co/iLj6hbu58Y

[CardiologyTalk @CardiologyTalk]

Phase 3 REDUCE-IT Trial Prakriti Gaba, MD @PrakritiGaba @DLBHATTMD @BrighamWomens @HarvardMed #REDUCEIT #CardioTwitter

https://t.co/IO6cmzddJP

[CardiologyTalk @CardiologyTalk]

Podcast - Non-RBC Blood Does Not Reduce Survival Following Surgery Ibrahim Sultan, MD @IbrahimSultanMD @HviUpmc @UPMC @UPMCPhysicianEd #CardioTwitter

Link to Audio:
https://t.co/OXFB8r0MBN

[CardiologyTalk @CardiologyTalk]

Non-RBC Blood Does Not Reduce Survival Following Surgery Ibrahim Sultan, MD @IbrahimSultanMD @HviUpmc @UPMC @UPMCPhysicianEd #CardioTwitter

https://t.co/MNx87avv8l

[CardiologyTalk @CardiologyTalk]

Epi Scar-Homogenization With VS Without Epicardial Ablation Andrea Natale, MD @natale_md @tcainstitute #VT #ICM

https://t.co/BxDTq9OzNi

[CardiologyTalk @CardiologyTalk]

Podcast - Epi Scar-Homogenization With VS Without Epicardial Ablation Andrea Natale, MD @natale_md @tcainstitute #VT #ICM

Link to Audio:
https://t.co/SQ7A6Zl00C

[CardiologyTalk @CardiologyTalk]

Phase III ORION-9,10, and 11 Studies Scott Wright, MD @ScottWrightMD @MayoClinic #ORIONStudies

https://t.co/J1UYcT1yzQ

[CardiologyTalk @CardiologyTalk]

Podcast - Phase III ORION-9,10, and 11 Studies Scott Wright, MD @ScottWrightMD @MayoClinic #ORIONStudies

Link to Audio:
https://t.co/NoSzcrqsD4

[CardiologyTalk @CardiologyTalk]

Phase 2 PACIFIC-AF Study Jonathan P. Piccini, MD @JonPicciniSr @DukeHeartCenter @DukeCardiology #PACIFICAF

https://t.co/69iih7aD8w

[CardiologyTalk @CardiologyTalk]

Podcast - Phase 2 PACIFIC-AF Study Jonathan P. Piccini, MD @JonPicciniSr @DukeHeartCenter @DukeCardiology #PACIFICAF

Link to Audio:
https://t.co/EeQvrSZLmX

[CardiologyTalk @CardiologyTalk]

Moving from “Candidacy” To “Benefit Derived” Drs. Lala and Mentz @dranulala @MountSinai @robmentz #JCF #wordsmatter

https://t.co/xFqyIp9UMv

[CardiologyTalk @CardiologyTalk]

Podcast - Moving from “Candidacy” To “Benefit Derived” Drs. Lala and Mentz @dranulala @MountSinai @robmentz #JCF #wordsmatter

Link to Audio:
https://t.co/kR17f0WhzG